Pharmaceutical Product Development, Inc. is a global contract research organization providing drug discovery and development services. Its clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. Its development services include preclinical programs and Phase I through Phase IV clinical development services, as well as bioanalytical, cGMP, global central laboratory and vaccines and biologics laboratory services. The Company operates in two segments: Development and Discovery Sciences. In May 2009, the Company completed its disposition of its wholly owned subsidiary Piedmont Research Center, LLC. In December 2009, the Company completed its disposition of its wholly owned subsidiary PPD Biomarker Discovery Sciences, LLC. On April 2, 2009, the Company acquired Magen BioSciences, Inc. On April 21, 2009, the Company acquired AbC.R.O., Inc. On November 6, 2009, the Company acquired Excel PharmaStudies, Inc.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:PPDI
CUSIPN/A
Phone+1-910-2510081
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
Pharmaceutical Product Development (NASDAQ:PPDI) Frequently Asked Questions
What is Pharmaceutical Product Development's stock symbol?
Pharmaceutical Product Development trades on the NASDAQ under the ticker symbol "PPDI."
Has Pharmaceutical Product Development been receiving favorable news coverage?
Press coverage about PPDI stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pharmaceutical Product Development earned a news impact score of 0.18 on Accern's scale. They also gave news coverage about the healthcare company an impact score of 47.08 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Pharmaceutical Product Development.
How do I buy shares of Pharmaceutical Product Development?
Shares of PPDI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Pharmaceutical Product Development?
Pharmaceutical Product Development's mailing address is 929 N Front St, WILMINGTON, NC 28401-3331, United States. The healthcare company can be reached via phone at +1-910-2510081.
MarketBeat Community Rating for Pharmaceutical Product Development (NASDAQ PPDI)
MarketBeat's community ratings are surveys of what our community members think about Pharmaceutical Product Development and other stocks. Vote "Outperform" if you believe PPDI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPDI will underperform the S&P 500 over the long term. You may vote once every thirty days.
